Daiichi Sankyo Company, Limited (DSNKY) 은(는) 상장 기업입니다 헬스케어 섹터의 제약 산업에서 운영. 본사 소재지는 Tokyo, 일본. 현재 CEO는 Hiroyuki Okuzawa.
DSNKY 을(를) 보유 IPO 날짜 2008-12-12, 18,726 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $34.34B.
Daiichi Sankyo Company, Limited is a global pharmaceutical company headquartered in Tokyo, Japan, engaged in the research, development, manufacturing, and marketing of a diverse portfolio of prescription and over-the-counter medicines. The company's key therapeutic areas include oncology, cardiology, diabetes, neurology, and infectious diseases, with notable products such as trastuzumab deruxtecan for cancer treatment, edoxaban for anticoagulation, and teneligliptin for diabetes management. Beyond pharmaceuticals, Daiichi Sankyo also operates in vaccines, animal health, cosmetics, medical devices, and active pharmaceutical ingredients. Founded in 1899, the company leverages strategic collaborations, including partnerships with diagnostic companies, to expand its competitive position in precision medicine and advanced therapies across major global markets.
